ClinicalTrials.gg
RecruitingNCT07702292Updated Sep 15, 2026

[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

A Phase 2 interventional study of [68Ga]BED003 in Colorectal Cancer, Epithelial Ovarian Cancer and Gastric Cancer (GC), sponsored by Blue Earth Diagnostics. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Blue Earth Diagnostics (part of Bracco) · Phase 2, Interventional, and Diagnostic

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 427 studies in Colorectal Neoplasms with a site in Italy — 102 open to participants now, 142 under way, 18 of them phase 3. Colorectal Neoplasms · Italy.

Planned enrollment
256th of 329
71 · median 215
Started
2026
with 10 others
Phase 2
113 of 427
18 open now
Primary completion
2028-02
later than 97 of 141 live
Registered
424th of 427
by date

Among the 427 studies in Colorectal Neoplasms with a site in Italy, this one is the 256th largest by planned enrollment of the 329 interventional ones that give a count, is one of 11 that started in 2026, is one of 113 in phase 2, reaches primary completion later than 97 of the 141 other live ones, and was the 424th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

102 of the 427 studies in Colorectal Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

96 more — sign in →

All 102 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 427 studies in Colorectal Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

This is a multi-centre, open-label, single-arm, Phase 2 study designed to evaluate the diagnostic performance of [68Ga]BED003 in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).

03

Conditions studied

  • Colorectal Cancer
  • Epithelial Ovarian Cancer
  • Gastric Cancer (GC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Invasive Lobular Breast Carcinoma

Keywords

  • Positron emission tomography
  • Fibroblast activation protein
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants provide and confirm that they are able and willing to comply with all protocol requirements.
  2. Participants must be ≥ 18 years and \< 80 years of age and competent to give informed consent.
  3. performance status ≤ 2.
  4. Women of (WOCBP) must have a negative serum test at screening and a negative urine pregnancy test at the PET/CT imaging visit (Visit 2) prior to [68Ga]BED003 administration.

    Note: If combining screening (Visit 1) and the PET/CT imaging visit (Visit 2) into a single visit, a serum pregnancy test must be used to exclude pregnancy.

  5. WOCBP, and men who are sexually active with WOCBP, must agree to use a highly-effective method(s) of from the PET/CT imaging visit (Day 1/Visit 2) to the safety follow-up telephone call (Day 3/Visit 3).
  6. Diagnosis of either CRC (confirmed by histopathology), GC (confirmed by histopathology), PDAC (confirmed by cytology or histopathology), ILC (confirmed by histopathology), or EOC (suspected or confirmed by cytology or histopathology).

    Note: Invasive breast cancer with mixed ductal/lobular histology is permitted.

  7. Conventional imaging performed within 8 weeks of screening (Visit 1) and no later than 24 hours before [68Ga]BED003 administration and available for sending to the central imaging vendor, including, at a minimum, a contrast-enhanced CT that includes the abdomen and pelvis.
  8. Either:

    1. Treatment-naïve with at least stage IIB disease. Available sample or scheduled biopsy or surgical resection no later than Day 42. Cytology of the primary lesion is acceptable for participants with PDAC who are not surgical candidates.
    2. Following therapy (with at least stage IIB disease at initial presentation) with scheduled biopsy or surgical resection no later than Day 42.
    3. Suspected recurrence after definitive therapy.

Exclusion criteria

Exclusion Criteria:

  1. Participants administered any radioisotope within 5 physical half-lives prior to [68Ga]BED003 administration.
  2. Participants administered any other IMP within 2 weeks or 5 half-lives, whichever is longest, prior to [68Ga]BED003 administration.
  3. Participants who have recently received any other contrast agent (\< 24 hours for IV agents and \< 5 days for oral agents) before the day of [68Ga]BED003 administration.
  4. Participants with a history of severe claustrophobia or panic attacks when in confined spaces.
  5. Known to [68Ga]BED003 or any of its constituents.
  6. Participants with any medical condition or other circumstances at screening or in their past medical history that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or study completion, including, but not limited to, the following:

    1. Any other primary cancers that could confound the interpretation of the study results.
    2. Major surgery (such as laparoscopy/laparotomy/thoracotomy) over the 3 months preceding screening that could confound the interpretation of the study results.
    3. Serious, non-healing wound, ulcer, or bone fracture.
    4. Active hepatitis.
    5. Significant cardiac disorders including recent (in last 3 months) myocardial infarction or (ECG) findings.
  7. Known diagnosis of an or inflammatory disorder that is expected to confound image interpretation per investigator judgement, excluding disorders directly related to the index cancer (e.g. tumour-associated pancreatitis or biliary stasis for PDAC).
  8. Medical history of abdomino-pelvic or breast irradiation in the last 3 months.
  9. Presence of any current implanted foreign material (e.g. stents, surgical clips) that may confound image interpretation per investigator judgement.
  10. Significant renal impairment, defined as an estimated (as determined by the Modification of Diet in Renal Disease formula) below 45 mL/min/1.73m2 or a serum creatinine > 1.5 × the .
  11. Female participants who are breastfeeding, unless the participant commits to pumping breast milk and discarding it from from the PET/CT imaging visit (Day 1/Visit 2) to the safety follow-up telephone call (Day 3/Visit 3).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (estimated)

Study arms

  • Experimental
    [68Ga]BED003

    Each participant will receive \[68Ga\]BED003 followed by positron emission tomography (PET)/computed tomography (CT) imaging at the PET/CT imaging visit (Visit 2).

    Drug: [68Ga]BED003

Interventions

  • Positron emission tomography (PET)/computed tomography (CT) imaging

06

What researchers measure

Primary outcomes

  1. Assess the diagnostic performance of [68Ga]BED003 in the peritoneum.

    Assess the diagnostic performance of \[68Ga\]BED003 in the peritoneum.

    Time frame: Until completion of follow-up procedures, up to 42 days post injection.

Secondary outcomes

  1. Further assess the diagnostic performance of [68Ga]BED003.

    Participant and region level diagnostic performance (where calculable: sensitivity, specificity, positive predictive value, and negative predictive value) with \[68Ga\]BED003 PET/CT compared to composite SOT and participant and region level detection rates

    Time frame: Until completion of follow-up procedures, up to 42 days post injection

  2. Semiquantitative assessment of [68Ga]BED003 tumour uptake.

    Standardised uptake values and tumour-to-background ratios.

    Time frame: Immediately following administration of [68Ga]BED003

  3. Evaluate the safety and tolerability of [68Ga]BED003.

    Incidence and severity of adverse events using CTCAE version 5.0.

    Time frame: From screening until safety follow-up (48 hours post injection).

  4. Confirm optimal timing of imaging following [68Ga]BED003 injection (first 6 participants).

    Comparison of tumour-to-background ratios and reader assessments of diagnostic quality.

    Time frame: Immediately following administration of [68Ga]BED003

  5. Confirm optimal [68Ga]BED003 administered activity (first 6 participants).

    Reader assessments of diagnostic quality based on simulated reduced count data.

    Time frame: Immediately following administration of [68Ga]BED003

07

Study locations

5 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Feb 2028, 20 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 20 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2026
First posted
Jul 14, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07702292
Collaborators
Medpace, Inc.
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Jun 30, 2026
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Sep 15, 2026

Study contacts

Jamie MacKay
Contact
contact@blueearthdx.com
44 (0)1865 507300
Jason Kane
Contact
contact@blueearthdx.com
44 (0)1865 507300

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium-68

Start the discussion